Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-09-27
2009-06-09
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S323000, C514S326000, C546S199000, C546S201000, C546S212000
Reexamination Certificate
active
07544700
ABSTRACT:
The present invention is related to sulfonamide derivatives having a lipophilic moiety and which are substantially soluble. Said compounds are notably for use as pharmaceutically active compounds. The present invention also related to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. The compounds of formula (I) according to the present invention being suitable pharmaceutical agents are those wherein Ar1 and Ar2 are independently from each other substituted or unsubstituted aryl or heteroaryl groups, X is O or S, preferably O; R1 is hydrogen or a C1-C6-alkyl group, or R1 forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar1; n is an integer from 0 to 5, preferably between 1-3 and most preferred 1; Y within formula (I) is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl which is substituted with at least one ionizable moiety to which a lipophilic chain is attached and which is containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula (I) thus providing a sulfonamide.
REFERENCES:
patent: 5238950 (1993-08-01), Clader et al.
patent: 5744320 (1998-04-01), Sherf et al.
patent: 2004/0077854 (2004-04-01), Halazy et al.
patent: 97 45403 (1997-12-01), None
patent: 98 53814 (1998-12-01), None
patent: 01 23378 (2001-04-01), None
Weston et al., The JNK Signal Transduction Pathway, Current Opinion in Genetics and Development, vol. 12, No. 1, pp. 14-21, Feb. 2002.
Hans Matter et al.: “Affinity and selectivity of matrix metalloproteinase inhibitors: A chemometrical study from the perspective of ligands and proteins” J. Med. Chem., vol. 42, No. 22, pp. 4506-4523, 1999.
Hans Matter et al.: “Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and x-ray structure analysis” J. Med. Chem., vol. 42, No. 11, pp. 1908-1920, 1999.
Database CHEMABS ′Online! Chemical Abstracts Service, Columbus, Ohio, US. Database accession No. 112:118396 XP002162631, 1989.
Database CHEMABS ′Online! Chemical Abstracts Service, Columbus, Ohio, US Database accession No. 111:189437, XP002162632, 1989.
Database CHEMABS ′Online! Chemical Abstracts Service, Columbus, Ohio, US Database accession No. 110:209560, XP002162633, 1984.
Database CHEMABS ′Online! Chemical Abstracts Service, Columbus, Ohio, US Databas accession No. 112:178264, XP002162634, 1989.
Roger J. Davis: “Signal trasduction by the JNK Group of MAP kinases” Cell, vol. 103, pp. 239-252 2000.
Yi-Rong Chen et al.: “The c-Jun N-terminal kinase pathway and apoptotic signaling” International Journal of Oncology, vol. 16, pp. 651-662 2000.
YT Ip et al.: “Signal transduction by the c-Jun N-terminal kinase (JNK) from c-Jun N-terminal kinase (JNK) from inflammation to development” Curr Opin Cell Biol, vol. 10, pp. 205-219 1998.
S. Leppa et al.: “Diverse functions of JNK signalling and c-Jun in stress response and apoptosis” Oncogene, vol. 18, No. 45, pp. 6158-6162 1999.
A. Minden et al.: “Regulation and function if the JNK subgroup of MAP kinases” Biochim Biophys Acta, vol. 1333, pp. F85-F104 1997.
A.J. Whitmarsh et al.: “Transcription factor AP-1: regulation by mitogen activated protein kinases signal transduction pathways” J. Mol, Med., vol. 77, pp. 2360-2371 1996.
S. Goupta et al.: “Selective interaction of JNK protein kinase isoforms with transcription factors” The EMBO Journal, vol. 158, No. 11, pp. 2760-2770 1996.
D. Derek et al.: “Absence of excitotoxicity- induced apoptosis in the hippocampus of mice lacking the Jnk3 gene” Nature, vol. 389, pp. 865-876 1997.
Loel H. Martin et al.: “Developmental expression in the mouse nervous system of the p493F12 SAP kinase” Molecular Brain Research, vol. 35, pp. 47-57 1996.
Y. Kumagae et al.: “Human c-Jun N-terminal kinase expression and activation in the nervous system” Molecular Brain Research, vol. 67, pp. 10-17 1999.
Calin D. Dumitru et al.: “TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway” Cell, vol. 103, pp. 1071-1083, 2000.
Z. Han et al.: “C-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis” The Journal of Clinical Investigation, vol. 108, No. 1, pp. 73-81, 2001.
H. Nishina et al.: “Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes” Jounrnal of Experimental Medicine, vol. 186, No. 6, pp. 941-953, 1997.
Stephan J. Kempiak et al.: “The Jun kinase cascade is responsible for activating the CD28 response element of the IL-2 promoter: proof of cross-talk with the IB kinase cascade” The Journal of Immunology, vol. 162, pp. 3176-3187, 1999.
S.M. De La Monte et al.: “Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells” J. Alzheimer's Dis., vol. 2, No. 3-4, pp. 261-281, 2000.
X. Zhu: “Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating n urons in Alzheimer's disease” Journal of Neurochemistry, vol. 76, pp. 435-441, 2001.
T. Force t al.: “Stress-activated protein kinases in cardiovascular disease” Circulation Research, vol. 78, pp. 947-953 1996.
S. Kim et al.: “Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat ballon-injured artery” Circulation, vol. 97, pp. 1731-1737 1998.
Q. Xu et al.: “Acute hypertension activates mitogen-activated protein kinases in arterial wall” The Journal of Clinical Investigation, vol. 97, No. 2, pp. 508-514 1996.
M.A. Bogoyevitch et al.: “Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfus d heart” Circulation Research, vol. 79, pp. 163-173, 1996.
CM Pombo et al.: “The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion” J. Biol. Chem., vol. 42, pp. 26546-26551, 1994.
I. Onishi et al.: “Activation of c-Jun N-terminal kinase during ischemia and reperfusion in mouse liver” FEBS Letters, vol. 420, pp. 201-204 1997.
R. Safirstein: “Renal stress response and acute renal failure” Adv. Ren. Replace Ther., vol. 4, No. 2 Suppl 1, pp. 38-42 1997.
L. Butterfield et al.: “C-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet” The Journal of Biological Chemitry, vol. 272, No. 15, pp. 10110-10116, 1997.
M. Hu et al.: “JNK2 and JNK3 are p53 N-terminal serine 34 kinases” Oncogene, vol. 15, pp. 2277-2287 1997.
X. Xu et al.: “Constitutively activated JNK is associated with HTLV-1 mediated tumorgenesis” Oncogene, vol. 13, pp. 135-142 1996.
YR Chen et al.: “The c-Jun N-terminal kinase pathway and apoptotic signaling” Int. J. Oncol., vol. 16, No. 4, pp. 651-662 2000.
T.C. Harding et al.: “Inhibition of JNK by overexpression of the JNK binding domain of JIP-1 prevents apoptosis in sympathetic neurons” The Journal of Biological Chemistry, vol. 276, No. 7, pp. 4531-4534, 2001.
AF Abdel-Magid et al.: “Reductive amination of aldehves and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures” Journal of Organic Chemistry, vol. 61, pp. 3849-3862, 1996.
L. Xu et al.: “As
Arkinstall Stephen J.
Biamonte Marco
Camps Montserrat
Church Dennis
Gotteland Jean-Pierre
Coleman Brenda L
Laboratoires Serono SA
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Pharmaceutically active sulfonamide derivatives bearing both... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutically active sulfonamide derivatives bearing both..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active sulfonamide derivatives bearing both... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4080133